** Shares of GH Research GHRS.O down 3.2% premarket to $15.79 after securing equity raise
** Irish biotech firm late Tues sold 10 mln shares at $15 for $150 mln gross proceeds
** Offering price represents 8.1% discount to stock's last sale of $16.32. Stock fell 9.3% on Tues
** On Mon, GHRS shares surged 70% to close at $17.99, highest since Apr 2022, after co said its depression therapy, GH001, met main goals of mid-stage study
** Co intends to use net offering proceeds to invest in research, clinical/technical development of current and/or additional product candidates, according to the SEC filing
** It has 52 mln shares outstanding for nearly $850 mln market cap
** Cantor, Stifel and RBC are jt bookrunners for the offering
** Sentiment on GHRS unanimously bullish among 5 analysts covering the stock and their median PT is $37, according to LSEG data
** Stock ended 2024 at $7
(Lance Tupper is a Reuters market analyst. The views expressed are his own)
((lance.tupper@tr.com 1-646-279-6380))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。